MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9900
-0.0500
-4.81%
Opening 10:09 03/03 EST
OPEN
1.000
PREV CLOSE
1.040
HIGH
1.020
LOW
0.9800
VOLUME
1.83M
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
0.3600
MARKET CAP
108.55M
P/E (TTM)
-1.9721
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: ORAGENICS INC
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following information should...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
8-K: ORAGENICS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/20 05:18
NVAX, GEVO, WATT and KOPN among premarket gainers
JMP Group (JMP) +114% on Q4 results.Vaccinex (VCNX) +88% on signing two multi-project deals.Energous Corporation (WATT) +59% after report Apple working on magnetic battery pack.Taoping (TAOP) +44% after entering into Consulting agreement with Great
Seekingalpha · 02/19 13:26
8-K: ORAGENICS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/12 14:02
BRIEF-Oragenics Announces Recent Capital Raise And Warrant Exercises Totaling $21.9 Million And The Redemption Of Its Series C Preferred Stock
reuters.com · 02/12 13:53
Oragenics secures $20M capital raise
Oragenics (OGEN) announces that it has raised about $20M from the sale of its shares through an agreement with A.G.P./Alliance Global Partners for an "at-the-market" facility.The company also received about
Seekingalpha · 02/12 13:14
Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock
Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock
Business Wire · 02/12 13:00
KalVista Pharmaceuticals, Heat Biologics leads healthcare gainers; Aeterna Zentaris, Ekso Bionics among major losers
Gainers: KalVista Pharmaceuticals KALV +134%, Heat Biologics HTBX +70%, Iterum Therapeutics (ITRM) +48%, OrganiGram OGI +47%, Oragenics (OGEN) +24%.Losers: Aeterna Zentaris (AEZS) -27%, Ekso Bionics EKSO -23%, Ocugen OCGN -23%, Hancock Jaffe Laboratories (...
Seekingalpha · 02/09 16:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OGEN. Analyze the recent business situations of ORAGENICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OGEN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 6.33M
% Owned: 6.89%
Shares Outstanding: 109.65M
TypeInstitutionsShares
Increased
4
857.31K
New
5
128.78K
Decreased
2
2.71M
Sold Out
2
2.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.23%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Director
Frederick Telling
President/Chief Executive Officer/Director
Alan Joslyn
Chief Financial Officer/Treasurer/Secretary
Michael Sullivan
Director
Kim Murphy
Independent Director
Alan Dunton
Independent Director
Robert Koski
Independent Director
Charles Pope
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About OGEN
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.